Alirocumab in Patients With Acute Myocardial Infarction
Status:
Completed
Trial end date:
2018-08-16
Target enrollment:
Participant gender:
Summary
Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an
inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to
high-intensity statin (atorvastatin 80 mg) in lowering low density lipoprotein (LDL)
cholesterol during non-ST segment elevation myocardial infarction (NSTEMI).